SALVARANI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 59.889
EU - Europa 21.782
AS - Asia 10.380
SA - Sud America 262
AF - Africa 107
OC - Oceania 102
Continente sconosciuto - Info sul continente non disponibili 44
Totale 92.566
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 59.329
GB - Regno Unito 7.982
IT - Italia 4.396
SG - Singapore 3.618
CN - Cina 3.030
SE - Svezia 2.329
DE - Germania 1.668
HK - Hong Kong 1.513
UA - Ucraina 1.451
TR - Turchia 1.116
FI - Finlandia 981
RU - Federazione Russa 850
BG - Bulgaria 749
FR - Francia 421
ID - Indonesia 408
CA - Canada 276
IE - Irlanda 231
BZ - Belize 221
NL - Olanda 214
JP - Giappone 181
BR - Brasile 162
IN - India 157
AU - Australia 85
LT - Lituania 77
VN - Vietnam 76
ES - Italia 68
BE - Belgio 57
CZ - Repubblica Ceca 57
CH - Svizzera 53
MX - Messico 50
IR - Iran 47
KR - Corea 42
PK - Pakistan 39
EU - Europa 38
MY - Malesia 37
PL - Polonia 33
TN - Tunisia 30
AR - Argentina 29
EG - Egitto 28
PT - Portogallo 24
CO - Colombia 22
CL - Cile 21
HU - Ungheria 19
NZ - Nuova Zelanda 17
PH - Filippine 17
RO - Romania 17
GR - Grecia 16
IL - Israele 16
IQ - Iraq 15
PE - Perù 15
RS - Serbia 15
ZA - Sudafrica 14
AT - Austria 12
DK - Danimarca 12
MA - Marocco 12
TW - Taiwan 10
EC - Ecuador 9
NO - Norvegia 9
BD - Bangladesh 7
DZ - Algeria 7
EE - Estonia 7
JO - Giordania 7
KE - Kenya 7
TH - Thailandia 7
HR - Croazia 6
NP - Nepal 6
AE - Emirati Arabi Uniti 5
LU - Lussemburgo 5
BY - Bielorussia 4
GH - Ghana 4
GT - Guatemala 4
LV - Lettonia 4
SA - Arabia Saudita 4
A2 - ???statistics.table.value.countryCode.A2??? 3
MD - Moldavia 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
VE - Venezuela 3
AL - Albania 2
AZ - Azerbaigian 2
CU - Cuba 2
JM - Giamaica 2
KG - Kirghizistan 2
KH - Cambogia 2
LB - Libano 2
LY - Libia 2
MK - Macedonia 2
MM - Myanmar 2
PS - Palestinian Territory 2
SI - Slovenia 2
SS - ???statistics.table.value.countryCode.SS??? 2
SY - Repubblica araba siriana 2
UG - Uganda 2
A1 - Anonimo 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CY - Cipro 1
DO - Repubblica Dominicana 1
Totale 92.557
Salva come PNG Salva come JPEG
Città #
Fairfield 8.611
Southend 6.696
Santa Clara 6.396
Woodbridge 5.935
Houston 4.031
Ashburn 3.801
Chandler 3.410
Seattle 3.141
Singapore 2.869
Wilmington 2.811
Jacksonville 2.750
Cambridge 2.624
Ann Arbor 2.339
Dearborn 1.911
Hong Kong 1.494
Modena 1.313
Nyköping 1.168
Beijing 1.016
San Diego 986
Princeton 777
Sofia 738
Eugene 560
San Jose 532
Helsinki 509
New York 458
Izmir 416
Jakarta 400
Moscow 396
London 332
Milan 253
Belize City 221
Dublin 206
Redwood City 198
Shanghai 194
Bologna 169
Las Vegas 161
Chicago 150
Boardman 138
Buffalo 129
Rome 123
Toronto 123
Dallas 117
Norwalk 108
Falls Church 105
Munich 103
Saint Louis 96
Bremen 95
Hefei 89
Parma 89
Frankfurt am Main 85
Nanjing 85
Kilburn 80
Reggio Nell'emilia 79
Kunming 68
Dong Ket 66
Albuquerque 62
Reggio Emilia 62
Guangzhou 61
Tokyo 61
Hounslow 59
Atlanta 53
Chiswick 52
Jinan 50
Columbus 49
Perth 46
Brussels 43
Florence 42
Padova 42
Brno 41
North York 38
Los Angeles 37
Prescot 37
Paris 36
Wuhan 36
Des Moines 34
Ankara 32
Ottawa 31
Amsterdam 30
Mumbai 30
São Paulo 30
Verona 30
Vigevano 30
Zurich 30
Naples 29
Grafing 28
Nanchang 28
Bari 27
Indiana 27
Shenyang 27
Council Bluffs 25
Lappeenranta 24
Washington 24
Genoa 23
Valencia 23
Zhengzhou 23
Groningen 21
Hangzhou 21
Islington 21
Turin 21
San Francisco 20
Totale 73.346
Salva come PNG Salva come JPEG
Nome #
Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis 988
COVID-19-associated vasculitis and thrombotic complications: from pathological findings to multidisciplinary discussion 393
Anti-TNF-α drugs differently affect the TNFa-sTNFR system and monocyte subsets in patients with psoriasis 318
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 289
Tocilizumab in patients with severe COVID-19: a retrospective cohort study 284
Corrigendum: Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy 276
Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis 275
Comment on: Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis: Reply 271
Adult Primary Central Nervous System Vasculitis 269
Prevalence of SARS-CoV-2 (Covid-19) in Italians and in immigrants in an area of Northern Italy (Reggio Emilia) 269
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register 242
CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease 241
Clinical features of polymyalgia rheumatica and giant cell arteritis 233
Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease 232
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice 222
G/R 241 polymorphism of intercellular adhesion molecule 1 (ICAM-1) is associated with Fuchs uveitis 221
Thalidomide, deep venous thrombosis and vasculitis 219
Nailfold capillaroscopic changes in dermatomyositis and polymyositis 213
Clinical Spectrum of Medium-Sized Vessel Vasculitis 212
Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 210
Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature 209
Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study 208
(18)F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis 207
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 205
-463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis 204
Recent advances in the diagnosis and treatment of polymyalgia rheumatica 204
Interferon Alpha-2a for the Treatment of Post-Infectious Uveitis Secondary to Presumed Intraocular Tuberculosis 203
Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature 202
Visual loss and other cranial ischaemic complications in giant cell arteritis 201
Biotherapies in large vessel vasculitis 199
2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative 199
Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study 198
Epidemiology of psoriatic arthritis 198
Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study 197
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility 196
An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease 196
Contrast-enhanced ultrasound of the carotid artery in patients with large vessel vasculitis: Correlation with positron emission tomography findings 195
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease 195
[18F]fluorodeoxyglucose positron emission tomography imaging in a case of relapsing polychondritis 195
Validation of the classification criteria for cryoglobulinaemic vasculitis 193
Comparison between colour duplex sonography findings and different histological patterns of temporal artery 192
Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study 192
2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative 191
Improving therapeutic options for patients with giant cell arteritis 191
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study 191
Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells 191
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 191
Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? 190
Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs 190
Imaging of vasculitis: State of the art 190
Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis 188
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine 187
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease 187
Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study 187
Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides 185
Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study 185
Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis 185
Are steroids alone sufficient for the treatment of giant cell arteritis? 185
Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis 184
Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? 184
Symptomatic psoriatic dactylitis is associated with ultrasound determined extra-synovial inflammatory features and shorter disease duration 184
Whole Exome Sequencing Identifies Rare Protein-Coding Variants in Behçet's Disease 183
Trial of Tocilizumab in Giant-Cell Arteritis 183
Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy 183
Relationship between plasma profiles of oxytocin and adrenocorticotropic hormone during suckling or breast stimulation in women 183
Management of primary and secondary central nervous system vasculitis 183
Giant cell arteritis: Involvement of intracranial arteries 182
NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica 182
Tocilizumab: a novel therapy for patients with large-vessel vasculitis 181
The role of infectious agents in the pathogenesis of vasculitis 181
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 181
Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study 181
2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative 180
Biologics in vasculitides: Where do we stand, where do we go from now? 179
Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations 179
Increased expression of interleukin-22 in patients with giant cell arteritis 179
MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis 179
Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT 179
Complex interplay between neutral and adaptive evolution shaped differential genomic background and disease susceptibility along the Italian peninsula 178
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial 178
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study 178
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 178
Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease 178
Primary CNS vasculitis with spinal cord involvement 177
Impact of demography and population dynamics on the genetic architecture of human longevity 177
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study 177
Incidence, prevalence and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period 176
64 Cu and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells 176
Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature 175
Pre-pregnancy counselling of patients with vasculitis 175
INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. WHAT DO WE DON’T KNOW? THE LIRA STUDY (LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS) 175
Psoriatic arthritis spondylitis radiology index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis 174
A putative functional variant within the UBAC2 gene is associated with increased risk of Behçet's disease 174
Idiopathic aortitis: an underrecognized vasculitis 174
Rapidly progressive primary central nervous system vasculitis 174
CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis 173
2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative 173
Comment on: Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature: Reply 173
Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs 173
Cervical interspinous bursitis in active polymyalgia rheumatica 172
Totale 20.767
Salva come PNG Salva come JPEG
Categoria #
all - tutte 430.044
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 430.044
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202011.136 0 0 0 0 0 2.634 3.044 1.749 1.702 622 971 414
2020/202115.857 1.387 927 1.146 1.847 1.511 1.125 1.429 1.947 1.016 1.604 919 999
2021/202213.164 620 1.475 1.334 950 369 965 861 631 1.513 943 2.021 1.482
2022/202310.863 1.386 756 738 798 1.307 1.559 243 1.046 1.697 225 597 511
2023/20248.281 335 532 425 849 1.815 486 515 1.469 246 216 374 1.019
2024/202512.709 1.171 353 400 2.006 4.686 4.093 0 0 0 0 0 0
Totale 94.475